1
← Back to quizzesFree quiz
Type 1 Diabetes Overview
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the destruction of pancreatic β‑cells, leading to absolute insulin deficiency. This comprehensive course synthesizes…
0 / 21
Score: 0%
2
A patient with established type 1 diabetes is switched from a basal insulin glargine U‑100 to glargine U‑300. What is the most likely effect on HbA1c?
3
Which of the following statements best explains why polyuria occurs when plasma glucose exceeds 180 mg/dL?
4
A 30‑year‑old adult with type 1 diabetes has a BMI of 24 kg/m², a family history of autoimmune disease, and recent ketonuria. Which test would most directly confirm endogenous insulin production?
5
During a severe viral infection, which counter‑regulatory hormone most directly accelerates gluconeogenesis, worsening hyperglycemia in type 1 diabetes?
6
A child with newly diagnosed type 1 diabetes presents with DKA. According to the review, what proportion of children present with DKA at diagnosis?
7
When calculating an insulin sensitivity factor (ISF) for a 45‑kg patient, which formula is appropriate?
8
Which of the following technologies provides interstitial glucose readings every 1‑5 minutes and can generate alarms for impending hypoglycemia?
9
A patient on an insulin pump experiences recurrent hypoglycemia despite CGM alerts. Which of the following is the most likely explanation according to the review?
10
Which adjunctive therapy is FDA‑approved for type 1 diabetes and works by slowing gastric emptying?
11
A 55‑year‑old with long‑standing type 1 diabetes has an eGFR of 45 mL/min/1.73 m² and albuminuria. According to the review, which class of medication should be added to the regimen to reduce renal risk?
12
During the DCCT, intensive insulin therapy reduced the incidence of retinopathy progression by approximately what percentage compared with conventional therapy?
13
A patient with type 1 diabetes is pregnant and wishes to achieve optimal glycemic control. Which fasting glucose target is recommended in the review?
14
Which of the following statements best describes the role of C‑peptide in the diagnosis of type 1 diabetes?
15
A 20‑year‑old with type 1 diabetes is considering an islet‑cell transplant. Which of the following is a major risk associated with this procedure as noted in the review?
16
Which of the following best explains why C‑peptide is a more reliable marker of endogenous insulin than insulin itself in patients receiving exogenous insulin?
17
A patient with type 1 diabetes is using a hybrid closed‑loop system that delivers rapid‑acting insulin. Which of the following statements about the system’s impact on HbA1c is most accurate?
18
According to the review, which of the following statements about the seasonal incidence of type 1 diabetes is correct?
19
A 9‑year‑old with newly diagnosed type 1 diabetes has a random plasma glucose of 210 mg/dL but no classic symptoms. Which additional test is recommended to confirm the diagnosis?
20
Which of the following best describes the relationship between insulin deficiency and GLUT4 translocation in type 1 diabetes?
21
A patient with type 1 diabetes is being considered for adjunctive metformin therapy. Which of the following is the most accurate statement regarding its expected effect based on the review?
Understanding Type 1 Diabetes: Pathophysiology, Diagnosis, and Management
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the destruction of pancreatic β‑cells, leading to absolute insulin deficiency. This comprehensive course synthesizes key concepts drawn from a clinical quiz, offering an educational deep‑dive for medical students, residents, and primary‑care clinicians. By the end of this module, you will be able to recognize classic presentations, interpret autoantibody panels, calculate insulin‑dosing parameters, and select modern glucose‑monitoring technologies.
1. Classic Clinical Presentation
Children and adolescents often present with the triad of polyuria, polydipsia, and unexplained weight loss. These symptoms arise from hyperglycemia‑induced osmotic diuresis and catabolic metabolism. In the quiz, a 12‑year‑old patient exemplifies this classic picture.
- Polyuria: Glucose exceeding the renal threshold (~180 mg/dL) draws water into the urine (osmotic diuresis).
- Polydipsia: Resulting fluid loss triggers thirst mechanisms.
- Weight loss: Lack of insulin prevents glucose utilization, prompting lipolysis and proteolysis.
Understanding why polyuria occurs is essential. When plasma glucose surpasses the renal threshold, the proximal tubule’s sodium‑glucose cotransporter (SGLT2) becomes saturated, and excess glucose remains in the tubular lumen, pulling water osmotically. This mechanism is the correct answer to the quiz question about polyuria.
2. Autoantibodies in Type 1 Diabetes
Autoimmune markers are pivotal for confirming the diagnosis and predicting disease progression. The most frequently detected autoantibody at diagnosis is the glutamic acid decarboxylase 65 autoantibody (GADA). Other antibodies include:
- Insulin autoantibodies (IAA)
- Insulinoma‑associated antigen‑2 autoantibodies (IA‑2A)
- Zinc transporter 8 autoantibodies (ZnT8A)
While all can be present, GADA has the highest prevalence in newly diagnosed patients, especially in children and adolescents.
3. Assessing Endogenous Insulin Production
Measuring C‑peptide is the gold standard for evaluating residual β‑cell function because it is co‑secreted with insulin in equimolar amounts and is not extracted by the liver. An undetectable C‑peptide level confirms absent endogenous insulin, which is the correct answer for the adult case with ketonuria. Elevated fasting insulin is misleading in T1DM because exogenous insulin does not affect C‑peptide.
4. Counter‑Regulatory Hormones and Hyperglycemia
During stress, infection, or illness, several hormones oppose insulin’s actions. The hormone most directly responsible for accelerating gluconeogenesis—and thereby worsening hyperglycemia—in T1DM is glucagon. Glucagon stimulates hepatic glucose production via glycogenolysis and gluconeogenesis, a critical consideration during sick‑day management.
5. Epidemiology of Diabetic Ketoacidosis (DKA) at Diagnosis
DKA remains a common initial presentation. Approximately 34 % of children present with DKA at the time of diagnosis, reflecting the importance of early recognition and prompt treatment. This statistic underscores the need for heightened vigilance in primary‑care settings.
6. Insulin Therapy: Basal Insulin Switches
When transitioning from insulin glargine U‑100 to the more concentrated glargine U‑300, clinical trials have demonstrated a modest but meaningful reduction in HbA1c—about 0.31 %—compared with older intermediate‑acting insulins. The longer, more stable pharmacokinetic profile of U‑300 improves basal coverage, reducing glycemic variability.
7. Calculating Insulin Sensitivity Factor (ISF)
The ISF helps determine how much one unit of rapid‑acting insulin will lower blood glucose. For a patient weighing 45 kg, the appropriate formula is:
ISF = 1800 ÷ weight (kg)
Thus, ISF = 1800 ÷ 45 ≈ 40 mg/dL per unit. This calculation is essential for safe correction dosing during hyperglycemia.
8. Modern Glucose Monitoring Technologies
Continuous glucose monitors (CGMs) have revolutionized diabetes care. A CGM with a skin‑worn sensor provides interstitial glucose readings every 1‑5 minutes and can generate real‑time alarms for impending hypoglycemia, empowering patients to act before severe events occur. This technology surpasses traditional finger‑stick glucometers, HbA1c assays, and urine dipsticks in both frequency and actionable data.
9. Integrating Knowledge into Clinical Practice
To translate these concepts into everyday care, consider the following checklist:
- Screen symptomatic children for polyuria/polydipsia and obtain a fasting glucose.
- Order a panel of autoantibodies (GADA, IA‑2A, ZnT8A, IAA) when T1DM is suspected.
- Measure C‑peptide if distinguishing between type 1 and type 2 diabetes.
- Educate patients on sick‑day rules: monitor glucose and ketones, adjust insulin, and seek medical care promptly.
- When initiating or intensifying basal insulin, consider glargine U‑300 for its modest HbA1c benefit and lower hypoglycemia risk.
- Calculate ISF using the 1800‑weight formula for accurate correction dosing.
- Recommend CGM use for patients who experience frequent hypoglycemia or have difficulty achieving glycemic targets.
10. Frequently Asked Questions (FAQ)
What is the renal glucose threshold and why does it matter?
The renal threshold (~180 mg/dL) is the plasma glucose concentration at which the kidneys can no longer reabsorb all filtered glucose. Above this level, glucose spills into urine, pulling water with it and causing osmotic diuresis.
Can autoantibody testing replace C‑peptide measurement?
No. Autoantibodies confirm autoimmune etiology, while C‑peptide quantifies residual insulin secretion. Both are complementary.
Is CGM appropriate for all patients with type 1 diabetes?
While CGM offers clear benefits, insurance coverage, patient preference, and ability to manage sensor data influence suitability. Most guidelines recommend CGM for anyone aiming for tight glycemic control.
Conclusion
Mastering the pathophysiology, diagnostic markers, and therapeutic nuances of type 1 diabetes equips clinicians to deliver evidence‑based, patient‑centered care. By integrating autoantibody interpretation, C‑peptide assessment, insulin dosing calculations, and cutting‑edge CGM technology, healthcare providers can improve outcomes, reduce DKA incidence, and enhance quality of life for individuals living with this chronic condition.
